| Description | Prasugrel Hydrochloride (LY 640315 Hydrochloride) is a piperazine derivative and pletelet aggregation inhibitor that is used to prevent thrombosis in patients with acute coronary syndrome. |
| In vivo | Prasugrel 在单剂量0.3至3 mg/kg及多剂量0.3及1 mg/kg/day范围内显著抑制动静脉（AV）分流和电刺激引起的动脉血栓形成。这些剂量与通过P2Y12受体抑制血小板活化的剂量相似，表明Prasugrel在这些脑梗塞和外周动脉闭塞性疾病模型中的保护作用反映了Prasugrel活性代谢物对血小板P2Y12的抑制。Prasugrel还显著防止外周血管病变的进展[1]。 |
| Target activity | Platelet:1.8 μM. |
| Synonyms | LY 640315, PCR 4099 (hydrochloride), 盐酸普拉格雷, Effient Hydrochloride, LY 640315 Hydrochloride, Prasugrel HCl |
| molecular weight | 409.9 |
| Molecular formula | C20H20FNO3S·HCl |
| CAS | 389574-19-0 |
| Storage | keep away from moisture,keep away from direct sunlight|Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | H2O: < 1 mg/mL (insoluble or slightly soluble) DMSO: 43 mg/mL (104.9 mM) Ethanol: 9 mg/mL (21.95 mM) |
| References | 1. Ogawa T, et al. Eur J Pharmacol. 2009, 612(1-3):29-34. |